We read with great interest the paper of Fonseca et al.
1 published on your journal and would like to make some considerations about this study.
The authors studied a small sample of predominantly Hispanic neonates, and although the high risk of hyperbilirubinemia in this population, they started phototherapy at very low total serum bilirubin (TSB) levels for term infants. The authors state that phototherapy was started according to the American Academy of Paediatrics guidelines. However, the reported TSB levels before phototherapy are very low to justify the treatment in the absence of hemolysis. Did the authors use prophylactic phototherapy? Tan and Dong 2 started phototherapy at really higher levels than those reported by Fonseca et al.
Surprisingly, TSB and transcutaneous bilirubin in covered skin (TcB-C) did not change during treatment, whereas transcutaneous bilirubin in exposed skin significantly decreased. How is this possible? It would have been relevant to know the ranges of TSB for each time point of evaluation, as well as the peak TSB reached by each infant. We recently published a paper on 364 newborn infants obtaining different results.
3 In fact, in our study we found similar significant reductions of TSB (from 13.6 ± 3.8 to 9.2±3.3 mg dl À1 ) and TcB-C (from 13.3±3.5 to 9.0 ± 3.6 mg dl À1 ) after 52 ± 33 h of phototherapy.
